AU6233501A - Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide - Google Patents

Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide

Info

Publication number
AU6233501A
AU6233501A AU62335/01A AU6233501A AU6233501A AU 6233501 A AU6233501 A AU 6233501A AU 62335/01 A AU62335/01 A AU 62335/01A AU 6233501 A AU6233501 A AU 6233501A AU 6233501 A AU6233501 A AU 6233501A
Authority
AU
Australia
Prior art keywords
neuropeptide
nucleic acid
sdf
acid molecule
sequence coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62335/01A
Other languages
English (en)
Inventor
Johannes Auer
Frank Bosse
Clemens Gillen
Marc Gleichmann
Hans-Werner Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax GmbH
Original Assignee
Rhein Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Biotech GmbH filed Critical Rhein Biotech GmbH
Publication of AU6233501A publication Critical patent/AU6233501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU62335/01A 2000-06-02 2001-06-01 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide Abandoned AU6233501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10027383A DE10027383A1 (de) 2000-06-02 2000-06-02 Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
DE10027383 2000-06-02
PCT/EP2001/006250 WO2001092530A1 (de) 2000-06-02 2001-06-01 Nukleinsäure-molekül umfassend eine für ein sdf-1 gamma chemokin, einen neuropeptid-präkursor oder mindestens ein neuropeptid kodierende nukleinsäuresequenz

Publications (1)

Publication Number Publication Date
AU6233501A true AU6233501A (en) 2001-12-11

Family

ID=7644466

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62335/01A Abandoned AU6233501A (en) 2000-06-02 2001-06-01 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide

Country Status (9)

Country Link
US (2) US20030215792A1 (enExample)
EP (1) EP1287142B1 (enExample)
JP (1) JP2004521607A (enExample)
AT (1) ATE309361T1 (enExample)
AU (1) AU6233501A (enExample)
DE (2) DE10027383A1 (enExample)
DK (1) DK1287142T3 (enExample)
ES (1) ES2251483T3 (enExample)
WO (1) WO2001092530A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004232972A1 (en) * 2003-04-16 2004-11-04 Argyll Biotechnologies, Llc Prophylactic and therapeutic benefits of new class of immune stimulating peptides
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
UA96926C2 (ru) * 2005-10-31 2011-12-26 Мерк Сероно Са Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
AU2007237840A1 (en) * 2006-04-07 2007-10-25 Neuro Therapeutics Ab Survival and development of neural cells
WO2008003780A2 (en) * 2006-07-07 2008-01-10 TRÖSCHER, Herbert Use of proteins of the sdf-1-family for improvement of axonal plasticity or for axonal regeneration following lesions
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2197907A2 (en) * 2007-10-15 2010-06-23 Centre National De La Recherche Scientifique-CNRS Cxcl12 gamma a chemokine and uses thereof
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US10662234B2 (en) 2011-06-07 2020-05-26 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
CA2117953C (en) * 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
US6114502A (en) * 1996-04-10 2000-09-05 Axys Pharmaceuticals, Inc. Gene family associated with neurosensory defects
EP0892807A1 (en) * 1996-04-10 1999-01-27 Axys Pharmaceuticals, Inc. Gene family associated with neurosensory defects
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
WO1999055915A2 (en) * 1998-04-29 1999-11-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF Xq13
AU5134799A (en) * 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
AU2201801A (en) * 1999-12-16 2001-06-25 Ribotargets Limited Assays

Also Published As

Publication number Publication date
EP1287142A1 (de) 2003-03-05
JP2004521607A (ja) 2004-07-22
WO2001092530A1 (de) 2001-12-06
EP1287142B1 (de) 2005-11-09
DK1287142T3 (da) 2006-03-13
US20030215792A1 (en) 2003-11-20
US20080319165A1 (en) 2008-12-25
DE50108009D1 (de) 2005-12-15
ATE309361T1 (de) 2005-11-15
ES2251483T3 (es) 2006-05-01
DE10027383A1 (de) 2001-12-20

Similar Documents

Publication Publication Date Title
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
WO2003018771A3 (en) A system for antibody expression and assembly
AU3368497A (en) Human dnase i hyperactive variants
WO2005049073A3 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
AU6233501A (en) Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide
HUP9903921A2 (hu) Tumor nekrózis faktorral rokon ligandum
ATE70280T1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
MY141459A (en) Recombinant anti-idiotypic antibodies
BR0108654A (pt) Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo
WO1990003435A3 (fr) Acide nucleique codant pour l'enzyme de conversion de l'angiotensine (eca) humaine, et ses applications, notamment pour le diagnostic in vitro de l'hypertension arterielle
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
AU2003240631A1 (en) A t cell subpopulation regulating gut immunity
EP1297147B8 (en) Compositions for the diagnosis and treatment of herpes simplex virus infection
DE60118359D1 (de) Humanische pellino-polypeptide
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
AR019864A1 (es) Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry
GB0120022D0 (en) Conjugate
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
TUINMAN et al. Analysis of the amino acid sequence of peptides by mass spectrometry An ion notation proposal

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase